Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Last trade$16.52
Day change+$0.62 (+3.90%)
Day range$15.66 – $16.65
Volume2,987,098
Market cap$1.62B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.62B
Price / earnings
—
Price / book
-4.31×
Price / sales
2.22×
EV / sales
2.01×
EV / EBITDA
-3.39×
Profitability
Earnings per share
-$5.14
Return on assets
-44.11%
Return on equity
139.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
1.4×
Quick ratio
1.25×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$441.77M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RARE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$173M
$214M
$136M
$207.28M
$160M
$167M
$139M
$164.65M
Cost of revenue
$32M
$34M
$30M
$29.35M
$28M
$23M
$29M
$17.17M
Gross profit
$141M
$180M
$106M
$177.93M
$132M
$144M
$110M
$147.48M
Selling, general and administrative
$97M
$88M
$88M
$87.94M
$87M
$87M
$87M
$81.89M
Research and development
$154M
$167M
$187M
$203.28M
$216M
$165M
$166M
$187.9M
Total operating expenses
$251M
$255M
$275M
$291.22M
$303M
$252M
$253M
$269.79M
Operating income
-$110M
-$75M
-$169M
-$113.28M
-$171M
-$108M
-$143M
-$122.31M
Interest expense
-$20M
-$22M
-$21M
-$19.47M
-$14M
-$14M
-$14M
-$15.48M
Income before taxes
-$127M
-$91M
-$184M
-$127.69M
-$179M
-$114M
-$150M
-$132.82M
Income taxes
-$9M
$1M
$1M
$870K
$1M
$1M
$1M
$384K
Net income
-$118M
-$92M
-$185M
-$128.56M
-$180M
-$115M
-$151M
-$133.2M
Net income attributable to common shareholders
-$118M
-$92M
-$185M
-$128.56M
-$180M
-$115M
-$151M
-$133.2M
EBITDA
-$101M
-$67M
-$161M
-$104.5M
-$163M
-$99M
-$134M
-$112.77M
Basic earnings per share
-$1.16
-$0.90
-$1.84
-$1.29
-$1.81
-$1.17
-$1.57
-$1.39
Diluted earnings per share
-$1.16
-$0.90
-$1.84
-$1.29
-$1.81
-$1.17
-$1.57
-$1.39
Recent news
Company coverage with links to the original publishers.
Ultragenyx announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111), an investigational gene therapy for MPS IIIA (Sanfilippo syndrome Type A). The company has also coordinated with NICE to align the evaluation timeline with the regulatory review process. The therapy received FDA approval in September 2026 and is also under review by the European Medicines Agency.
Ultragenyx (RARE) reported a quarterly loss of $1.16 per share, slightly missing the consensus estimate of $1.15, with revenues of $173 million falling 6.11% short of expectations. Despite underperforming the market by 29.1% year-to-date, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 44% of sectors.
Ultragenyx reported Q3 2026 revenue of $173 million, up 8.2% year-over-year but missing the consensus estimate of $184.25 million by 6.11%. EPS improved to -$1.16 from -$1.81 a year ago, slightly beating the -$1.15 estimate. Key product revenues showed mixed results: Dojolvi and Evkeeza exceeded expectations with strong growth, while Crysvita revenue fell short of estimates. The stock has gained 12.4% over the past month and holds a Zacks Rank #2 (Buy) rating.
Cytek Biosciences is expected to report a year-over-year earnings decline with higher revenues when it releases Q3 2026 results on November 4. The company is projected to post a quarterly loss of $0.08 per share with revenues of $52.9 million (up 1.2% YoY). With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has failed to beat consensus EPS estimates in the last four quarters.
GlaxoSmithKline (GSK) reported quarterly earnings of $1.47 per share, beating consensus estimates of $1.40 and delivering a 5% earnings surprise. Revenue of $11.95 billion also exceeded expectations by 1.24%. However, GSK shares have gained only 3.9% year-to-date versus the S&P 500's 12.8% gain. The stock maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.